The Lawsuits Nobody Priced

Snapchat’s fentanyl lawsuits were in the federal court system for over a year before the stock started pricing the risk. Families of teenagers who died from fentanyl purchased through the platform filed suit. Motions to dismiss were denied. Discovery was underway. Internal documents about Snap’s knowledge of drug sales on the platform were being subpoenaed.

All of this was public. Docket entries are public records. Court motions are public records. Judicial opinions are public records. But PACER, the federal court’s electronic filing system, charges per page. Court documents read like a foreign language to anyone without legal training. So the market overlooked it.

That’s an overstatement for large-cap litigation that analysts actively track. But for mid-cap and smaller companies, and for cases in sectors that equity analysts don’t specialize in, docket activity genuinely gets overlooked. The Snap fentanyl cases lived in that gap: serious enough to survive dismissal, not yet prominent enough for the sell-side to model.

What follows is how to read court dockets as an investor: which stages of litigation actually create financial risk, and what to look for.

Federal Court Data: What’s Available

Federal court data is public, but accessing it has historically been painful. PACER charges per page (with quarterly fee caps for small users). There are 94 federal district courts, each with its own search interface. Tracking cases across jurisdictions used to require either a law firm or an expensive litigation analytics subscription.

That’s changed. Open-source projects now archive millions of federal court dockets from volunteer-contributed PACER data. These archives are searchable, free, and extensive enough for serious screening. They don’t have every document (the archive depends on what users have downloaded), but they cover enough to identify active cases, track their stage, and spot patterns across companies.

I run court data searches as part of my research pipeline. One query per company returns matching cases with the basics: case name, court, date filed, cause of action, docket number. I can filter by case type (civil, bankruptcy, criminal, multidistrict litigation) and date range, then pull full details for cases that look relevant.

What you’ll miss: state courts

One important limitation. Federal court archives cover federal cases. Many significant lawsuits, especially product liability, consumer protection, and environmental cases, are filed in state court. State court docket data is fragmented across thousands of courts with varying levels of digitization. If your target company faces major litigation in state court, federal docket searches won’t surface it. Check the company’s 10-K legal proceedings section (Item 3) as a complement, since companies are required to disclose material litigation regardless of jurisdiction.

The Litigation Lifecycle: What Matters for Investors

Not all lawsuits matter for investment analysis. Most die early. The litigation lifecycle has distinct stages, and each stage tells you something different about the risk.

Stage 1: Filing. A complaint is filed. This has minimal investment signal by itself. Anyone can file a lawsuit. The filing alone tells you someone has a grievance, not that the grievance has merit.

Exception: if the plaintiff is a government agency (DOJ, SEC, FTC, state AG), the filing itself carries weight. Government agencies investigate before filing.

Stage 2: Motion to Dismiss. The defendant almost always moves to dismiss. The court decides: does the complaint, taken as true, state a legal claim? If the court DENIES the motion to dismiss, the case has survived its first test. A judge has determined the allegations, if proven, constitute a viable legal claim.

This is the first investment-relevant signal. Most investors don’t track motion to dismiss rulings because they require reading a judicial opinion written in legal jargon. But the outcome is binary: case lives or case dies. The docket entry tells you which happened.

Stage 3: Discovery. After surviving dismissal, parties exchange documents, take depositions, and subpoena records. This is where smoking guns surface. Internal emails about known product defects. Board minutes discussing undisclosed risks. Executive text messages contradicting public statements.

Discovery disputes (motions to compel, fights over privilege) are particularly informative. If a company is fighting hard to prevent document production, those documents probably contain something damaging.

Stage 4: Class Certification. For putative class actions, the court decides whether individual claims can proceed as a class. If certified, damages scale dramatically. One plaintiff’s claim of $50,000 becomes 100,000 plaintiffs’ claims totaling $5 billion.

Stage 5: Summary Judgment. The last off-ramp before trial. If denied for the defendant, the case is going to a jury. Juries are unpredictable. The uncertainty premium should be priced but often isn’t.

Stage 6: Settlement or Verdict. The endpoint. Settlements are often sealed. Verdicts are public. By this stage, the market is usually paying attention. The informational advantage tends to be earlier in the lifecycle, before the case becomes financial news.

Sizing the Risk: A Materiality Framework

Finding active litigation is only the first step. The harder question: does it matter financially?

Not every lawsuit with a denied motion to dismiss threatens a stock price. A $5 million product liability case against a $50 billion company is immaterial. Here’s the framework I use to decide whether litigation is worth tracking:

Damages relative to market cap and cash flow

The rough test: could a worst-case verdict or settlement materially impact the company’s market cap, earnings, or cash flow? “Material” is subjective, but I use 5% of market cap as a rough starting threshold (this is a rule of thumb, not a legal definition of materiality). If potential damages are below that, the litigation is unlikely to move the stock meaningfully.

For class actions, estimate the class size and per-plaintiff damages. For MDLs, look at comparable settlements in similar cases (opioid, talc, earplug precedents provide benchmarks).

Insurance and indemnification

Check the 10-K for insurance disclosures. Many companies carry product liability, D&O, or general liability insurance that covers litigation costs and settlements up to policy limits. If the company has robust insurance, even a large verdict might not impact shareholders. This is easier to confirm by reading the insurance footnote in the 10-K than by guessing.

Stage weighting

Not all stages carry equal weight:

  • Filing only: minimal. I note it but don’t act on it.
  • Motion to dismiss denied: moderate. The case has legal merit. Worth monitoring.
  • Class certified: significant. Damages just scaled by orders of magnitude.
  • Discovery producing damaging evidence: high. Especially if discovery disputes suggest the company is hiding documents.
  • Summary judgment denied: high. Going to a jury.

I weight later-stage cases more heavily than early-stage cases when assessing overall litigation risk for a company.

Multidistrict Litigation (MDL): Scale Risk

When dozens or hundreds of similar cases are filed across different courts, the Judicial Panel on Multidistrict Litigation can consolidate them into a single proceeding before one judge. This is MDL.

MDL consolidation means the litigation risk is systemic, not isolated. Multiple plaintiffs, multiple jurisdictions, similar fact patterns. One grievance might be a disgruntled customer. An MDL with 500 cases is a product failure, a pattern of harm, or a systemic fraud.

Equity analysts routinely underestimate MDL risk. “It’s just litigation” appears in analyst notes alongside “buy” ratings. Until the settlement reserves appear on the balance sheet.

Historical examples of MDL stock impact:

  • Opioid manufacturers: Purdue Pharma, Mallinckrodt, Endo International. MDL consolidation preceded bankruptcy filings.
  • 3M earplug litigation: MDL 2885, one of the largest MDLs in history by case count. 3M eventually spun off its healthcare division and used bankruptcy to contain the liability.
  • Johnson & Johnson talc litigation: MDL led to a $8.9 billion settlement proposal after multiple jury verdicts.

When I search court data, I specifically filter for MDL cases. If a company I’m researching is a defendant in an active MDL, the scale of the risk is likely much larger than any single case suggests.

Key Docket Entries to Watch

A full docket can be hundreds of entries. Most are procedural. The entries worth reading:

  • “Order Denying Motion to Dismiss”: case survives. Discovery begins. First real investment signal.
  • “Order Granting Class Certification”: damages scale from individual to class-wide.
  • “Discovery Dispute” / “Motion to Compel”: one side fighting document production. Usually the defendant resisting disclosure.
  • “Scheduling Order”: sets deadlines for discovery, motions, and trial. Makes the risk time-bound. Useful for options expiration selection (Guide 1).
  • “Settlement Conference” / “Mediation Order”: parties talking resolution. Could accelerate or delay.
  • “Unsealed Document” / “Order to Unseal”: previously sealed information becoming public. Often the catalyst moment.
  • “Notice of Bankruptcy Filing”: automatic stay halts the case. Claims become bankruptcy claims. Different game entirely.

The Case That Didn’t Matter

Not every denied motion to dismiss leads to financial impact. I spent time building a thesis around a consumer products company facing a class action over product labeling. Motion to dismiss denied. Class certification pending. Damages looked potentially significant relative to the company’s market cap.

What I underestimated: the company’s insurance coverage. Their D&O and product liability policies covered the litigation costs and potential settlement up to limits that exceeded the realistic damages estimate. The case eventually settled for a meaningful number, but the insurance covered it. Stock didn’t move.

I didn’t appreciate how much insurance changes the math until that one. A case can be legally significant and financially immaterial if the company is well-insured. This is in the 10-K footnotes, usually under “Commitments and Contingencies” or in the insurance discussion.

The Timing Opportunity

Litigation timelines are notoriously unpredictable. Judges grant continuances. Discovery gets extended. Settlement talks stall and restart. A case scheduled for trial in March gets pushed to September.

This unpredictability creates an options pricing opportunity.

The market doesn’t like timing uncertainty. When a catalyst has an uncertain date, options pricing tends to spread the risk thinly across many expirations rather than concentrating it in one. This means options covering a litigation catalyst window are often cheaper than they should be relative to the potential magnitude of the move.

If the scheduling order sets dispositive motions for August and trial for November, I’m not buying November expiry. I’m buying February or March. Judges grant continuances frequently in complex cases. The extra theta cost prevents a correct thesis from expiring one month too early.

For MDL proceedings, timelines stretch further. “Bellwether” trials (test cases selected from the MDL pool) often get pushed back by a year or more. Size expiration accordingly.

Cross-Referencing: Where Court Data Gets Powerful

Court docket data becomes a grey swan signal when combined with other data sources from this series.

Docket + 8-K mentioning “legal proceedings”: the company is disclosing the litigation. Read the disclosure carefully: does it characterize the risk accurately? A company facing an MDL with 200 cases describing it as “various legal proceedings, none of which management believes will have a material adverse effect” is either confident in their defense or minimizing. Check which by reading the docket.

Docket + NO 8-K or 10-K mention: the company has active litigation that it’s not disclosing. Either they’ve determined it’s immaterial (possible) or they’re hoping it goes away (also possible). If the case has survived a motion to dismiss and entered discovery, the “immaterial” argument gets harder to make.

Docket + insider selling cluster: insiders selling while the company faces progressing litigation. The insiders know about the cases. Their decision to sell in this context is more informative than selling in a vacuum.

Docket + analyst silence: no sell-side analyst mentions the litigation in their model. The docket shows the case is active, past MTD, in discovery. The analyst report says “buy” with a price target that implies zero litigation risk.

Each combination adds conviction. No single data point is sufficient. The convergence of independent signals, each from free public databases, is what makes the research defensible.

Blind Spots

Court docket analysis has real limitations:

  • State court blind spots. Federal court archives don’t cover state courts. Significant litigation can live in state court for years without appearing in federal docket searches.
  • Settlement amounts are often sealed. You’ll know a case settled but not for how much. This makes it hard to calibrate future outcomes from past settlements.
  • Litigation can drag for years. A case in discovery can stay there for 2-3 years. If you buy options on a litigation thesis, you’re fighting theta the entire time. The thesis can be right and the trade can still lose if timing is off.
  • Companies with good defense counsel win. A denied motion to dismiss doesn’t mean the plaintiff wins. Many cases that survive dismissal still settle for immaterial amounts or are won by the defendant at summary judgment or trial. Stage 2 (MTD denied) is a necessary condition, not a sufficient one.
  • Insurance covers more than you think. As noted above, well-insured companies can absorb litigation outcomes that look scary on paper.

If You Only Do Three Things

  1. Check docket stage, not just case count. Five lawsuits at the filing stage are less concerning than one lawsuit that has survived a motion to dismiss and entered discovery. Stage matters more than volume.
  2. Size the risk against market cap. Estimate potential damages and compare to the company’s market cap and free cash flow. Check insurance disclosures. Not every active lawsuit is material.
  3. Cross-reference with what the company discloses. Compare the court docket to the company’s 10-K legal proceedings section. If the docket shows progressing litigation and the 10-K barely mentions it, that’s a disclosure gap worth investigating.